AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12027348 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 31
Study 12027348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11475728 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Methotrexate (MTX) and Ectopic Pregnancy 2 (EP2) decoction
Number of subjects: 78
Study 11475728 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 78
Study 7539185 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytotherapeutic agents
Number of subjects: 0
Study 2693073 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.225 mg/day for the first week, increased to 0.450 mg/day for the second week)
Number of subjects: 24
Study 2693073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 359562 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin combined with sulfinpyrazone
Number of subjects: 103
Study 359562 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 103
Study 30954969 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual tapering of csDMARDs
Number of subjects: 189
Study 30954969 — intervention group
Group type: COMPARATOR
Intervention: Gradual tapering of TNF inhibitors
Number of subjects: 189
Study 30954969 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual tapering of csDMARDs and TNF inhibitors
Number of subjects: 189
Study 28084083 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass
Number of subjects: 50
Study 28084083 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass
Number of subjects: 50
Study 27141690 — intervention group
Group type: EXPERIMENTAL
Intervention: EA‐STEMI
Number of subjects: 196
Study 27141690 — intervention group
Group type: COMPARATOR
Intervention: AS‐STEMI
Number of subjects: 196
Study 23044410 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training session with ankle mass on non-paretic limb
Number of subjects: 60
Study 23044410 — intervention group
Group type: COMPARATOR
Intervention: Gait training session without ankle mass on non-paretic limb
Number of subjects: 60
Study 23044410 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground gait training
Number of subjects: 60
Study 23044410 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill gait training
Number of subjects: 60
Study 21604206 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based skin antiseptics (5 different solutions)
Number of subjects: 30
Study 21604206 — intervention group
Group type: COMPARATOR
Intervention: Reference alcohol 70% propan-2-ol
Number of subjects: 30
Study 20079220 — intervention group
Group type: EXPERIMENTAL
Intervention: New lesions (Group A)
Number of subjects: 192
Study 20079220 — intervention group
Group type: EXPERIMENTAL
Intervention: Late thrombosis (Group B)
Number of subjects: 192
Study 20079220 — intervention group
Group type: EXPERIMENTAL
Intervention: Average time from previous PCI to AMI
Number of subjects: 192
Study 20079220 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 192
Study 20079220 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 192
Study 16780618 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled incisional regional analgesia (PCRA) with ropivacaine 0.25% and 0.5%
Number of subjects: 60
Study 16780618 — intervention group
Group type: COMPARATOR
Intervention: Oral analgesics (paracetamol 1 g four times a day and ibuprofen 500 mg three times a day)
Number of subjects: 60
Study 14982911 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured DBP at home (average of 6 measurements per day during 1 week; n = 203)
Number of subjects: 400
Study 14982911 — intervention group
Group type: COMPARATOR
Intervention: Average of 3 sitting DBP readings at the physician's office (n = 197)
Number of subjects: 400
Study 11169172 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% NaCl solution
Number of subjects: 10
Study 11169172 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 10
Study 9007921 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic (2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 35
Study 9007921 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 35
Study 8285181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 26
Study 8285181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8285181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (in subset with hypertension)
Number of subjects: 26
Study 8285181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (in subset with type II diabetes and overt proteinuria)
Number of subjects: 26
Study 8285181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (in blacks)
Number of subjects: 26
Study 31482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drug (ATD) therapy
Number of subjects: 1186
Study 31482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive iodine (131I) therapy
Number of subjects: 1186
Study 31482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 1186
Study 31482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Second course of ATD
Number of subjects: 1186
Study 31482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative treatment (surgery or 131I)
Number of subjects: 1186
Study 31482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine replacement
Number of subjects: 1186
Study 31482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal thyroid hormone status without thyroxine supplementation
Number of subjects: 1186
Study 31482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients feeling fully recovered
Number of subjects: 1186
Study 30249609 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual GP care
Number of subjects: 235
Study 27247869 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50
Study 27247869 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 50
Study 24553426 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular drinkers (mild, moderate, heavy)
Number of subjects: 3542
Study 24553426 — intervention group
Group type: COMPARATOR
Intervention: Abstainers and irregular drinkers
Number of subjects: 3542
Study 24553426 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1229984 G→A polymorphism
Number of subjects: 3542
Study 22374410 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic resource use (mean of 20.3 days in the past 365 days)
Number of subjects: 3958
Study 22374410 — intervention group
Group type: COMPARATOR
Intervention: Residency teaching clinics
Number of subjects: 3958
Study 22374410 — intervention group
Group type: COMPARATOR
Intervention: Hospital inpatient practices
Number of subjects: 3958
Study 22374410 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 3958
Study 20932293 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team training in a medical simulation centre
Number of subjects: 4800
Study 20932293 — intervention group
Group type: COMPARATOR
Intervention: Control arm without any team training
Number of subjects: 4800
Study 17706223 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 concentration >= 1.04 pg/mL
Number of subjects: 71
Study 17706223 — intervention group
Group type: COMPARATOR
Intervention: IL-10 concentration < 1.04 pg/mL
Number of subjects: 71
Study 17706223 — intervention group
Group type: EXPERIMENTAL
Intervention: One standard deviation increase in baseline IL-10 concentration
Number of subjects: 71
Study 17706223 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 concentration in diabetics
Number of subjects: 71
Study 15735461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand/rotary/ultrasound technique (1 min of ultrasonic irrigation)
Number of subjects: 31
Study 15735461 — intervention group
Group type: COMPARATOR
Intervention: Hand/rotary technique
Number of subjects: 31
Study 15735461 — intervention group
Group type: COMPARATOR
Intervention: Histologic controls (5 uninstrumented mandibular molars)
Number of subjects: 31
Study 15189605 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed behaviors during dyadic interactions
Number of subjects: 158
Study 15189605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant behavior
Number of subjects: 158
Study 15189605 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendly behavior
Number of subjects: 158
Study 10585065 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 57
Study 10585065 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (mitomycin C 10 mg/m2, vinblastine 6 mg/m2, cisplatin 100 mg/m2)
Number of subjects: 57
Study 8913128 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashlight test
Number of subjects: 96
Study 8913128 — intervention group
Group type: EXPERIMENTAL
Intervention: Van Herick's test
Number of subjects: 96
Study 8913128 — intervention group
Group type: COMPARATOR
Intervention: Gonioscopy (gold standard)
Number of subjects: 96
Study 1830257 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme under the guidance of a health care professional
Number of subjects: 558
Study 1830257 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme under the guidance of a fellow patient
Number of subjects: 558
Study 1830257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education programme)
Number of subjects: 558
Study 6338164 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone phosphate (100 mg administered within 6 hours of the accident)
Number of subjects: 161
Study 6338164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 30901053 — intervention group
Group type: COMPARATOR
Intervention: No financial incentive
Number of subjects: 897
Study 30901053 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional $10 incentive
Number of subjects: 897
Study 30901053 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional $10 incentive
Number of subjects: 897
Study 30901053 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional lottery with a 1-in-10 chance of winning $100
Number of subjects: 897
Study 29953476 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy (X)
Number of subjects: 0
Study 29953476 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus oxaliplatin (XELOX)
Number of subjects: 0
Study 28134601 — intervention group
Group type: EXPERIMENTAL
Intervention: Natix alone
Number of subjects: 24
Study 28134601 — intervention group
Group type: COMPARATOR
Intervention: Bio-Oss plus collagen membrane
Number of subjects: 24
Study 25082832 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 3000
Study 25082832 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use among current smokers
Number of subjects: 3000
Study 25082832 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use among never-smokers
Number of subjects: 3000
Study 25082832 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use among ex-smokers
Number of subjects: 3000
Study 25082832 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in smoking habits among regular e-cigarette users
Number of subjects: 3000
Study 22781792 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombopoietin (TPO) 300 U×kg(‐1)×d(‐1) starting from day +1
Number of subjects: 120
Study 22781792 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombopoietin (TPO) 300 U×kg(‐1)×d(‐1) starting from day +4
Number of subjects: 120
Study 22781792 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombopoietin (TPO) 300 U×kg(‐1)×d(‐1) starting from day +7
Number of subjects: 120
Study 22781792 — intervention group
Group type: COMPARATOR
Intervention: Control group without TPO (Group A)
Number of subjects: 120
Study 20193551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (P group)
Number of subjects: 80
Study 20193551 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (NP group)
Number of subjects: 80
Study 17483009 — intervention group
Group type: EXPERIMENTAL
Intervention: Applephenon (1200 mg/d)
Number of subjects: 18
Study 17483009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1000 mg/d)
Number of subjects: 18
Study 17483009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15156310 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic stable intramedullary nailing (ESIN)
Number of subjects: 112
Study 11593916 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 10 mg/kg BW bid for 2 weeks
Number of subjects: 18
Study 11593916 — intervention group
Group type: COMPARATOR
Intervention: Placebo and paracetamol as needed
Number of subjects: 18
Study 9589685 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day, orally for 8 weeks)
Number of subjects: 40
Study 9589685 — intervention group
Group type: COMPARATOR
Intervention: GnRH analog (one ampule every 28 days for 2 months)
Number of subjects: 40
Study 9589685 — intervention group
Group type: COMPARATOR
Intervention: GnRH analog plus naltrexone (for 2 months)
Number of subjects: 40
Study 8059817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic screening (two screening sonograms at 15 to 22 weeks and 31 to 35 weeks)
Number of subjects: 15281
Study 8059817 — intervention group
Group type: COMPARATOR
Intervention: Conventional obstetric care (ultrasonography used only as determined by clinical judgment)
Number of subjects: 15281
Study 8059817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic screening
Number of subjects: 15281
Study 8059817 — intervention group
Group type: COMPARATOR
Intervention: Conventional obstetric care
Number of subjects: 15281
Study 2929297 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic bandage
Number of subjects: 68
Study 2929297 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 68
Study 30944985 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation-guided imagery
Number of subjects: 60
Study 30944985 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 26658899 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline malate (CM) 8 g dextrose + 8 g CM
Number of subjects: 15
Study 26658899 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 g dextrose)
Number of subjects: 15
Study 24213780 — intervention group
Group type: EXPERIMENTAL
Intervention: Education session plus motivational interview and two self-regulation coaching sessions
Number of subjects: 78
Study 24213780 — intervention group
Group type: COMPARATOR
Intervention: Control group (group-based patient education session led by a physical therapist)
Number of subjects: 78
Study 22451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia extract (20 mg, 2 tablets per day)
Number of subjects: 0
Study 22451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia extract (20 mg, 1 tablet per day)
Number of subjects: 0
Study 22451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia extract (1000 and 3000 mg/kg) in rats
Number of subjects: 0
Study 22451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia extract (various doses) in rats
Number of subjects: 0
Study 21321292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus rituximab
Number of subjects: 104
Study 18801781 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICE programme (n = 72)
Number of subjects: 144
Study 18801781 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 72)
Number of subjects: 144
Study 17081623 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta treatment
Number of subjects: 0
Study 17081623 — intervention group
Group type: COMPARATOR
Intervention: CD4(+) CD45R0(+) CD26(high) memory T lymphocytes
Number of subjects: 0
Study 14996484 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 35
Study 14996484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin
Number of subjects: 35
Study 14996484 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 35
Study 11518042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 3-week inpatient rehabilitation course
Number of subjects: 25
Study 11518042 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 consecutive SpA patients)
Number of subjects: 25
Study 11518042 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year follow-up for study patients
Number of subjects: 25
Study 9489643 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPC infusion over 1 day
Number of subjects: 60
Study 9489643 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPC infusion over 2 days
Number of subjects: 60
Study 9489643 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPC infusion over 3 days
Number of subjects: 60
Study 9489643 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPC infusion as a single infusion
Number of subjects: 60
Study 9489643 — intervention group
Group type: COMPARATOR
Intervention: PBPC infusion over 1, 2 or 3 days
Number of subjects: 60
Study 8165854 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dose schedule (40 micrograms each at 0, 1, 2, and 6 months)
Number of subjects: 0
Study 8165854 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose schedule (40 micrograms each at 0, 1, and 6 months)
Number of subjects: 0
Study 8165854 — intervention group
Group type: COMPARATOR
Intervention: Three-dose schedule (half the amount of vaccine) in healthy controls
Number of subjects: 0
Study 8165854 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dose schedule
Number of subjects: 0
Study 8165854 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose schedule
Number of subjects: 0
Study 8165854 — intervention group
Group type: COMPARATOR
Intervention: Three-dose schedule in healthy controls
Number of subjects: 0
Study 8165854 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dose and three-dose schedules
Number of subjects: 0
Study 3073355 — intervention group
Group type: EXPERIMENTAL
Intervention: TISACID (Al-Mg-hydroxy-carbonate)
Number of subjects: 0
Study 3073355 — intervention group
Group type: EXPERIMENTAL
Intervention: TISACID (Al-Mg-hydroxy-carbonate) with cimetidine
Number of subjects: 0
Study 31652554 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2,000 IU/day)
Number of subjects: 417
Study 31652554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 29637322 — intervention group
Group type: EXPERIMENTAL
Intervention: Early education treatment group
Number of subjects: 0
Study 29637322 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 29637322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive early educational treatment
Number of subjects: 0
Study 29637322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-benefit analysis
Number of subjects: 0
Study 27196675 — intervention group
Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir (LDV/SOF)
Number of subjects: 493
Study 27196675 — intervention group
Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir (LDV/SOF) + ribavirin (RBV)
Number of subjects: 493
Study 27196675 — intervention group
Group type: EXPERIMENTAL
Intervention: sofosbuvir (SOF) + ribavirin (RBV)
Number of subjects: 493
Study 24981505 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based HIV testing and counseling (HTC) intervention
Number of subjects: 0
Study 22162542 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir 750 mg every 8 hours from day 8 through day 23
Number of subjects: 24
Study 19935778 — intervention group
Group type: EXPERIMENTAL
Intervention: TD101 (siRNA)
Number of subjects: 1
Study 19935778 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 1
Study 17397308 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate chip (CHIP group)
Number of subjects: 42
Study 17397308 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP group)
Number of subjects: 42
Study 15759167 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Language Impairment (SLI) children
Number of subjects: 138
Study 15759167 — intervention group
Group type: COMPARATOR
Intervention: Language Impairment (LI) children
Number of subjects: 138
Study 15759167 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory short-term memory assessment
Number of subjects: 138
Study 12222545 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-gauge, 5/16-inch insulin syringe
Number of subjects: 124
Study 12222545 — intervention group
Group type: COMPARATOR
Intervention: 26-gauge, 3/8-inch tuberculin syringe
Number of subjects: 124
Study 10520785 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive percutaneous transluminal coronary angioplasty (PTCA) after DCA
Number of subjects: 225
Study 10520785 — intervention group
Group type: COMPARATOR
Intervention: Stand-alone DCA
Number of subjects: 225
Study 10520785 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive PTCA
Number of subjects: 225
Study 10520785 — intervention group
Group type: COMPARATOR
Intervention: DCA alone
Number of subjects: 225
Study 7486603 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-mg dose of nimodipine
Number of subjects: 12
Study 7486603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7486603 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-mg dose of nimodipine
Number of subjects: 12
Study 2138490 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium chloride (0.15 mg kg‐1) during nitrous oxide-fentanyl-thiopentone anaesthesia (BAL group)
Number of subjects: 72
Study 2138490 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium chloride (0.15 mg kg‐1) during nitrous oxide-halothane anaesthesia (HAL group)
Number of subjects: 72
Study 2138490 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium chloride (various doses)
Number of subjects: 72
Study 7328681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex therapy
Number of subjects: 48
Study 7328681 — intervention group
Group type: COMPARATOR
Intervention: Communication therapy
Number of subjects: 48